$Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma$

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma

Bibliographic Details
Main Authors:	Sridurga Mithraprabhu, John Reynolds, Rose Turner, Hang Quach, Noemi Horvath, Ian Kerridge, Anna Kalff, Krystal Bergin, Jay Hocking, Flora Yuen, Tiffany Khong, Brian M. Durie, Andrew Spencer
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-02-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00796-9

Similar Items

DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients
by: Sridurga Mithraprabhu, et al.
Published: (2019-06-01)

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies
by: Jay Hocking, et al.
Published: (2016-06-01)

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
by: Sridurga Mithraprabhu, et al.
Published: (2018-06-01)

Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients
by: Maoshan Chen, et al.
Published: (2019-06-01)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
by: Rose Turner, et al.
Published: (2022-05-01)

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
by: Ioanna Savvidou, et al.
Published: (2022-02-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
by: Parva Bhatt, et al.
Published: (2023-02-01)

Optimal sequencing in the management of relapsed/refractory myeloma patients
by: Philippe Moreau
Published: (2018-06-01)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
by: Klaus Podar, et al.
Published: (2021-10-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY
by: María-Victoria Mateos, et al.
Published: (2015-07-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2012-01-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2011-12-01)

Promising therapeutic approaches for relapsed/refractory multiple myeloma
by: Beiwen Ni, et al.
Published: (2022-12-01)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
by: Katja Weisel, et al.
Published: (2020-08-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Pomalidomide in the management of relapsed/refractory multiple myeloma: A review
by: Sergej Semochkin
Published: (2023-08-01)

Advances and perspective of the immunotherapy for relapsed/refractory multiple myeloma (interview)
by: S. V. Semochkin
Published: (2022-01-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Treatment of relapsed, refractory multiple myeloma: focus on new drugs
by: Angelo Maiolino
Published: (2020-10-01)

Current Status and Challenges in Treatment of Relapsed/Refractory Multiple Myeloma
by: WAN Yike, et al.
Published: (2019-09-01)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
by: Christopher T. Su, et al.
Published: (2021-07-01)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
by: Melody R. Becnel, et al.
Published: (2020-12-01)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
by: Mary H. Young, et al.
Published: (2021-08-01)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
by: Utkarsh Goel, et al.
Published: (2023-01-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020-11-01)

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
by: Samantha Pozzi, et al.
Published: (2021-10-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies
by: Rebecca Crawford, et al.
Published: (2022-11-01)

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
by: Josh N. Vo, et al.
Published: (2022-06-01)